Join
Live feed
·
PRReleasevia Quantisnow
Regeneron Pharmaceuticals Inc. logo

ESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLC

ByQuantisnow·Wall Street's wire, on your screen.
REGN· Regeneron Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track REGN (Regeneron Pharmaceuticals Inc.) and more on Quantisnow.